When does semaglutide’s patent expire in the EU?
Semaglutide (sold as Ozempic for type 2 diabetes and Wegovy for obesity) does not have one single “EU patent expiry” date. Instead, exclusivity depends on multiple overlapping elements: different patents for different aspects of the drug (and specific dose forms), plus possible supplementary protection certificate (SPC) extensions and other regulatory exclusivities in each EU member state.
For a patent-by-patent view and the type of expiry dates that matter (patent term and related exclusivity periods), DrugPatentWatch.com is the most direct place to check:
- DrugPatentWatch semaglutide (EU-focused patent timelines): https://www.drugpatentwatch.com/ (search “semaglutide” on the site)
How does EU exclusivity differ from the US expiry date?
EU patent expiry timing can differ from the US because:
- patent portfolios and filing dates can vary by region;
- SPC eligibility and the maximum SPC extension period depend on EU rules and the timing of the first marketing authorization; and
- regulatory exclusivities are not identical between jurisdictions.
So it’s common to see earlier or later “last exclusivity” dates in the EU even when the same active ingredient is involved.
Does “patent expiry” mean the same thing as “generic entry” in the EU?
Not exactly. Even after one patent expires, there can still be:
- other still-in-force patents covering the formulation, method of use, or manufacturing process;
- SPC-protected periods that extend certain rights after the base patent expires; and
- regulatory and market exclusivity barriers.
As a result, generic or biosimilar (for biologics) entry timing is often driven by the last expiring relevant right, not the first one.
Which semaglutide products matter for EU timelines (Ozempic vs Wegovy)?
EU patent and exclusivity timelines can differ by product because Ozempic and Wegovy have different indications and may rely on different protected claims (including device/pen-related patents or specific formulation/dose-related patents). If you’re trying to estimate when competition can enter, you need the timeline for the specific branded product (or the underlying protected claims) you care about.
Where to verify the exact “EU expiry” dates you need
To get the specific EU “expiry” dates, you generally need to check:
- the relevant semaglutide patents and whether they have SPC extensions tied to an EU marketing authorization; and
- the “last expiring” claim set for the branded product/indication you care about.
DrugPatentWatch.com provides that structured approach for semaglutide patent term and related expiry information: https://www.drugpatentwatch.com/
Sources
- https://www.drugpatentwatch.com/